Sionna Therapeutics reports smaller-than-expected Q4 net loss

Sionna Therapeutics

02/03/2026 12:11

Overview

Biopharmaceutical firm reports  Q4 net loss of -$20.44 mln

Company maintains strong cash position, expected to fund operations into 2028

Company advancing clinical pipeline with ongoing trials for NBD1 stabilizers

Outlook

Sionna's cash position expected to fund operations into 2028

Result Drivers

R&D EXPENSES - Research and development expenses were $15.2 million for the fourth quarter of 2025. Increased R&D expenses driven by development of clinical pipeline, particularly for NBD1 stabilizers

Cash, cash equivalents and marketable securities totaled $310.3 million as of December 31, 2025

Company press release: ID:nGNX4ByJZX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Beat
-$20.44 mln
-$24.58 mln (8 Analysts)
Q4 Basic EPS
-$0.46
Q4 Income from Operations
-$23.61 mln
Q4 Operating Expenses
$23.61 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sionna Therapeutics Inc is $52.00, about 42.3% above its February 27 closing price of $36.54

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)